Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $57 | $29 | $116 | $365 |
| Short-Term Investments | $97 | $172 | $103 | $31 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $4 | $6 | $3 |
| Total Curr. Assets | $158 | $231 | $259 | $400 |
| Property Plant & Equip (Net) | $5 | $6 | $1 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $11 | $39 | $105 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $2 | $2 | $0 |
| Total NC Assets | $15 | $48 | $108 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $174 | $279 | $367 | $401 |
| Liabilities | – | – | – | – |
| Payables | $2 | $3 | $3 | $4 |
| Short-Term Debt | $1 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $9 | $13 | $9 | $3 |
| Total Curr. Liab. | $12 | $17 | $12 | $7 |
| LT Debt | $2 | $3 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $2 | $3 | $35 | $0 |
| Other Liabilities | $0 | $0 | -$35 | $0 |
| Cap. Leases | $2 | $4 | $0 | $0 |
| Total Liabilities | $14 | $20 | $12 | $7 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $401 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$372 | -$259 | -$143 | -$53 |
| AOCI | -$0 | -$1 | -$1 | -$0 |
| Other Equity | $531 | $484 | $463 | $447 |
| Total Equity | $159 | $223 | $319 | $393 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $35 | $35 | $0 |
| Total Liab. & Tot. Equity | $174 | $279 | $367 | $401 |
| Net Debt | -$54 | -$25 | -$116 | -$365 |